In February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of my favorite stocks. Shares have jumped by more than 20,000% since then.

I believe we are about to do it again with this new AI project called Stargate

John Bolger Biography and Net Worth

Director of Fulgent Genetics

John Bolger is a member of our Board of Directors and head of our Audit Committee. Mr. Bolger has extensive public company board and audit committee experience, having served as a director and audit committee chair of the following publicly traded companies for various terms during the period from 1993 to 2010: Integrated Device Technology, Inc., Sanmina Corp., Data Race, Inc., TCSI, Inc., Integrated Systems, Inc., Wind River Systems, Inc., Mission West Property, Inc., Cogent, Micromuse, Inc., JNI and Mattson Technology. Mr. Bolger also served as Vice President, Chief Financial and Administrative Officer of Cisco Systems, Inc., a manufacturer of computer networking systems, from 1989 to 1992. Mr. Bolger received a B.A. from the University of Massachusetts and an M.B.A. from Harvard University and he is a Certified Public Accountant. Mr. Bolger was selected to serve on our board of directors based on his more than 30 years of accounting and financial expertise, as well as his extensive public company board and senior management experience.

What is John C. Bolger's net worth?: The estimated net worth of John C. Bolger is at least $35,580.00 as of June 3rd, 2021. Mr. Bolger owns 2,000 shares of Fulgent Genetics stock worth more than $35,580 as of November 14th. This net worth evaluation does not reflect any other assets that Mr. Bolger may own. Learn More about John C. Bolger's net worth.
How do I contact John C. Bolger?: The corporate mailing address for Mr. Bolger and other Fulgent Genetics executives is 4978 SANTA ANITA AVENUE, TEMPLE CITY CA, 91780. Fulgent Genetics can also be reached via phone at (626) 350-0537 and via email at [email protected]. Learn More on John C. Bolger's contact information.
Has John C. Bolger been buying or selling shares of Fulgent Genetics?: John C. Bolger has not been actively trading shares of Fulgent Genetics during the last quarter. Most recently, John C. Bolger sold 936 shares of the business's stock in a transaction on Monday, August 30th. The shares were sold at an average price of $91.29, for a transaction totalling $85,447.44. Learn More on John C. Bolger's trading history.
Who are Fulgent Genetics' active insiders?: Fulgent Genetics' insider roster includes John Bolger (Director), Hanlin Gao (Insider), Ming Hsieh (Chairman & CEO ), Paul Kim (CFO), and Jian Xie (COO). Learn More on Fulgent Genetics' active insiders.
Are insiders buying or selling shares of Fulgent Genetics?: During the last twelve months, insiders at the sold shares 9 times. They sold a total of 32,464 shares worth more than $850,501.04. The most recent insider tranaction occured on August, 27th when insider Hanlin Gao sold 563 shares worth more than $12,853.29. Insiders at Fulgent Genetics own 31.8% of the company. Learn More about insider trades at Fulgent Genetics.
Information on this page was last updated on 8/27/2024.

John C. Bolger Insider Trading History at Fulgent Genetics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/30/2021	Sell	936	$91.29	$85,447.44
6/3/2021	Sell	125	$74.17	$9,271.25	2,000
3/9/2021	Sell	3,374	$101.62	$342,865.88	1,312
11/17/2020	Sell	4,269	$44.24	$188,860.56	4,644
8/17/2020	Sell	3,914	$40.87	$159,965.18	5,927
5/22/2020	Sell	8,677	$15.36	$133,278.72	9,342

John C. Bolger Buying and Selling Activity at Fulgent Genetics

Fulgent Genetics Company Overview

Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.

Today's Range

Now: $17.79

$17.65

$18.60

50 Day Range

MA: $20.85

$18.42

$22.91

2 Week Range

Now: $17.79

$17.65

$30.68

Volume

294,612 shs

Average Volume

181,668 shs

Market Capitalization

$544.20 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.51

Bill Gates’s Next Big AI Bet: Stargate

From Brownstone Research | Ad